Management Team

David J. Mazzo, PhD

Chief Executive Officer and Director

Bio
David J. Mazzo was appointed as Caladrius' Chief Executive Officer and as a member of our Board on January 5, 2015. Dr. Mazzo brings to the Company over 30 years of experience in the pharmaceutical industry. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc., a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulene SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the Board of Avanir Pharmaceuticals, Inc., a biotechnology company which was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of pSivida Corp., a publicly held biopharmaceutical company, in the role of non-executive chairman.

Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Douglas W. Losordo, MD, FACC, FAHA

Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer

Bio
Dr. Losordo was appointed Chief Medical Officer of the Company effective August 5, 2013. Dr. Losordo served from 2006 to 2013 as a member of the Scientific Advisory Board of Caladrius. Prior to his appointment as the Company’s Chief Medical Officer, Dr. Losordo served as Vice President, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International from October 2011 through February 2013. He is an adjunct professor of medicine at Northwestern University in Chicago, Illinois. From 2006 through 2011, Dr. Losordo was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. From 2004 through 2006, he was a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston. He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Losordo’s major research interests encompass angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, and vascular biology. He received his M.D. from the University of Vermont.

Dr. Losordo has engaged in career-long efforts to develop novel therapeutics and as a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals. Since 2012, he has served on the Scientific Advisory Board of The Stem For Life Foundation, a public charity devoted to accelerating development of cell therapies.

Raj Prabhakar

Senior Vice President, Business Development

Bio
Since 2015, Raj Prabhakar has served as Head of Business Development, and reports directly to CEO Dr. David Mazzo. Raj leads all out-licensing, in-licensing, M&A and partnership opportunities, and serves on the Executive Committee of Caladrius Biosciences. Current priorities include global partnerships for each of the investigational clinical candidates in immune-oncology, immune-modulation and cardiovascular indications, in addition to manufacturing JVs and acquisitions.

Prior to Caladrius Biosciences, Raj Prabhakar served as Vice President and Head of Business Development for Celsion Corporation from 2004 to 2015, including the acquisition of EGEN, Inc. a gene therapy and delivery company. At Celsion-EGEN, he led partnerships for immune-oncology gene therapy, small molecules, new formulations, and oligonucleotide delivery for DNA, RNA and gene editing candidates. Raj has particular transaction experience in Asia-Pacific with leading pharmaceutical companies in Japan and China. Prior to Celsion Raj was employed at PATH Global Vaccine Development Group, Protiveris, Osiris Therapeutics, and Harvard Medical School-Brigham & Women’s Hospital in multiple corporate development, business development, commercialization and research roles. Raj holds an MBA from the Harvard Business School and dual Bachelors of Science Degrees in Biology and Mechanical Engineering from the Massachusetts Institute of Technology.

Robert A. Preti, PhD

Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer, and Director

Bio
Robert “Bob” Preti is PCT’s co-founder and the visionary behind its successful growth and development strategy over much of the last two decades.

Bob built PCT to meet a recognized need for high quality manufacturing and development services in an emerging industry. As the cell therapy field has grown, so too has PCT- the company has now served over 100 Clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s Client-focused model that helps bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice. His vision for PCT includes expansion of its manufacturing capacity in the U.S. and Europe, as well as the development of new technological and engineering innovations that will help streamline and automate many cell processing techniques, leading to faster scale up, appropriate cost of goods, and robust quality for the industry.

Before assuming his role at PCT, Bob held a number of positions within the cellular therapy and blood banking fields. From 1996 to 1999, he was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center in Hackensack, N.J. He served in several capacities with the New York Blood Center from 1990 to 1997, including tissue bank director, director of hematopoietic stem cell processing, scientific director and associate investigator. He also worked as a research scientist for Marrow-Tech Incorporated, which went on to become Advanced Tissue Sciences (ATIS), where work in his laboratory lead to the Dermagraft product currently marketed by Organogenesis.
Bob began his career in academics, teaching first as an elementary and secondary level educator, then as an adjunct assistant professor and lecturer at Hunter College, an assistant professor at Queensborough Community College, and then adjunct assistant professor at York College. He also has served as clinical assistant professor of medicine for New York Medical College in Valhalla, N.Y.

Also active in the public health arena, Bob has served on the Stem Cell Banking Committee and Cord Blood Subcommittee of the New York State Department of Health and on the New Jersey State Department of Health’s Blood Bank Advisory Committee, chairing the Hematopoietic Progenitor Cell Processing Subcommittee. In addition, he has served in a leadership capacity for many professional organizations, including treasurer and founding member of the International Society of Hematotherapy and Graft Engineering, now called ISCT (International Society for Cellular Therapy). He has published and presented extensively on a variety of topics relating to cellular therapies. He recently completed a five year term as a director for AABB, and is currently Chairman for the Alliance for Regenerative Medicine (ARM), where, among other activities, he previously served as Vice Chairman from 2015 to 2016 and co-chaired the Standards and Technology Committee.

As Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer and a Director of Caladrius Biosciences, Bob is involved in assessing and directing the development of Caladrius Biosciences’ cell therapy pipeline, as well as participating in setting Caladrius' strategic direction.

Bob holds a BS degree in biology from Fordham University, and a MS degree and Doctorate, both in biology, from New York University

Joseph Talamo

Senior Vice President and Chief Financial Officer

Bio
Joseph Talamo was promoted to Senior Vice President and Chief Financial Officer in October 2015 from his previous role when he joined Caladrius in 2011 as the Corporate Controller and Chief Accounting Officer. He is a versatile finance executive with leadership experience in publicly-traded development and commercial-stage companies, along with a strong background in SEC compliance. He has led companywide forecasting, planning and analysis activities, including for M&A, and has had extensive experience with integrating transactions and raising capital. At Caladrius, Mr. Talamo has been responsible for numerous financial functions including SEC reporting, forecasting, planning and analysis, cash management and accounting.

Prior to joining Caladrius, from 1996 to 2010, Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. (“OSI”), a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010.

Mr. Talamo received a BBA in accounting from Hofstra University in 1991, and an MBA in finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.

Todd Girolamo, JD

General Counsel and Corporate Secretary

Bio
Todd Girolamo joined Caladrius in 2011. He is a seasoned attorney specializing in health-related products and businesses. As a member of the Caladrius senior management team, Mr. Girolamo has been responsible for managing all legal aspects of the Company’s research and development pipeline, from preclinical research to multinational pivotal clinical trials, including academic and corporate collaborations. He has been responsible for the Company’s licensing activities, the strategy, maintenance and prosecution of the Company’s extensive global patent estate and the management of all litigation involving the Company and its subsidiaries.

Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator, practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.

Mr. Girolamo received a Bachelor of Arts from Harvard College, a Juris Doctor from the University of Pennsylvania Law School and a Master of Business Administration from Columbia Business School.

David Schloss

Vice President, Human Resources

Bio
David Schloss, a senior human resources executive and former attorney with over 20 years of leadership experience, joined Caladrius Biosciences in 2014 as Vice President, Human Resources. At the company, Mr. Schloss is responsible for the development and delivery of compensation; benefits; organizational design and development; recruitment; and employee relations.

Mr. Schloss comes to Caladrius (formerly NeoStem) with a strong resume of experience in the pharmaceutical and biotechnology industries. Prior to joining Caladrius, he served as SVP, Human Resources with PLUS Diagnostics (acquired by Miraca Life Sciences). Prior to PLUS Diagnostics, Mr. Schloss led human resources for OraPharma from 2011- 2012, a private equity owned specialty pharmaceutical company focused on oral health care. Mr. Schloss helped grow the company and was instrumental in its acquisition and integration by Valeant Pharmaceuticals International. Prior to OraPharma, from 2009-2011, Mr. Schloss was Vice President, Human Resources for Eurand Pharmaceuticals, a publicly traded specialty pharmaceutical company based in Italy that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products. While with Eurand, Mr. Schloss helped build the commercial organization that launched Zenpep® for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Eurand was acquired by Aptalis in 2011.

From 2007-2009, Mr. Schloss led human resources for ImClone Systems, a fully integrated global biopharmaceutical company, engaged in the development and commercialization of a portfolio of targeted biological oncology treatments. He also led ImClone System’s human resources through its acquisition by Eli Lilly in 2008. Additionally, Mr. Schloss spent 17 years with GlaxoSmithKline in a number of senior level HR roles across the US and internationally.

Before beginning his career in human resources, Mr. Schloss was an attorney practicing in the representation of management in all phases of labor relations and employment law. He earned a BA from Clark University and a J.D. from the University of Miami School Of Law. He currently serves on the Pennsylvania Advisory Board of the Devereux Foundation, a leading nonprofit behavioral health organization that provides support and services to children and adults with intellectual, emotional, developmental, and behavioral challenges.

Greg Berkin

Vice President, Information Technology

Bio
M.S. (computer science/computer forensics) Fairleigh Dickinson University

Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Applications, Business Solutions, and Telecom.

Before joining Caladrius, Greg held director and management roles in IT at companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.

Greg has more than 20 years in the technical profession with 15 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, and cybersecurity.